| Pharmaceutical Information |
| Drug Name |
Temoporfin |
| Drug ID |
BADD_D02149 |
| Description |
Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan. |
| Indications and Usage |
For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XD05 |
| DrugBank ID |
DB11630
|
| KEGG ID |
D06066
|
| MeSH ID |
C072269
|
| PubChem ID |
60751
|
| TTD Drug ID |
D0P5DG
|
| NDC Product Code |
Not Available |
| UNII |
FU21S769PF
|
| Synonyms |
temoporfin | m-THPC | mTHPC | meso-tetrahydroxyphenyl chlorin | meso-tetrahydroxyphenylchlorin | 5,10,15,20-tetra(m-hydroxyphenyl)chlorin | meso-tetra-(hydroxyphenyl)chlorin | Foscan | Foslip |
|
| Chemical Information |
| Molecular Formula |
C44H32N4O4 |
| CAS Registry Number |
122341-38-2 |
| SMILES |
C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=CC(=CC=C7
)O)C8=CC(=CC=C8)O)C9=CC(=CC=C9)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
